Send to

Choose Destination
Int J Gynecol Cancer. 2019 Oct;29(8):1258-1263. doi: 10.1136/ijgc-2019-000440. Epub 2019 Jul 17.

Neutrophilia and mortality in women with uterine carcinosarcoma.

Author information

Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, United States.
Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut, United States.
Northwell Health and Hofstra School of Medicine, New Hyde Park, New York, United States.
Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut, United States
Contributed equally



The objective of this study was to investigate the relationship between pre-treatment absolute neutrophil count and clinical outcomes in patients with uterine carcinosarcoma.


In an Institutional Review Board approved, retrospective cohort study of 103 patients with uterine carcinosarcoma, the pre-treatment absolute neutrophil count data were obtained from the medical records, along with clinical, pathologic, treatment, and outcome data. Kaplan-Meier survival estimates were calculated and compared by the log rank test. Univariable and multivariable Cox proportional hazard regression models were used to examine the relationship of pre-treatment absolute neutrophil count with progression-free survival and overall survival.


Uterine carcinosarcoma patients in the highest quartile of pre-treatment absolute neutrophil count had significantly reduced progression-free survival (p<0.001, log rank test), and overall survival (p<0.001, log rank test), compared with patients in the lower absolute neutrophil count quartiles. On multivariable analysis, high absolute neutrophil count was an independent poor prognostic factor for disease recurrence, HR 2.97 (95% CI 1.35 to 6.53, p=0.007) for highest versus lowest quartile absolute neutrophil count, and for mortality, HR 4.43 (95% CI 1.64 to 12.00, p= 0.003).


High pre-treatment absolute neutrophil count is an independent poor prognostic factor in patients with uterine carcinosarcoma and may be useful as a potential biomarker in clinical trials. The mechanistic relationship of neutrophilia and uterine carcinosarcoma progression merits further investigation.


carcinosarcoma; preoperative care; uterine cancer


Conflict of interest statement

Competing interests: None declared.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center